CD86 and Recurrent upper respiratory tract infections: Similar results were observed in clinical trials, reporting that the oral administration of LC-Plasma for 14 days could increase CD86 and HLA-DR expression, thus reducing the number of incidences (days) of upper respiratory tract infection in male athletes undergoing high-intensity exercise [31].